Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin to enhance subsequent endocrine therapy in ER-positive HER2-normal metastatic breast cancer
2020-004909-32Phase 2Completed
- Sponsor
- Department of Oncology
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of eribulin in breast cancer, sponsored by Department of Oncology. Primary endpoint: Primary: Time to treatment failure comparison. Started Nov 2020; status: completed.
02
Drugs
eribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2020-004909-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004909-32.